Improved sleep quality in older adults with insomnia reduces biomarkers of disease risk: Pilot results from a randomized controlled comparative efficacy trial

Abstract

Importance Sleep disturbances have been linked to increased morbidity and mortality, yet it is unknown whether improving sleep quality in older adult patients with insomnia alters biomarkers of diabetes and cardiovascular disease risk. Objective Determine the comparative efficacy of cognitive behavioral therapy (CBT), tai chi chih (TCC), and a sleep seminar control (SS) to reduce multisystem biomarkers of disease risk in older adults with insomnia. Design Randomized controlled comparative efficacy trial. Setting Los Angeles community Participants A population-based sample of 109 older adults with chronic and primary insomnia Intervention Random assignment to CBT, TCC, or SS for 2-hour group sessions weekly over 4 months with a 16-month evaluation (1 year after follow-up). Main Outcome(s) and Measure(s) Multisystem biological risk comprised of 8 biomarkers: high-density lipoprotein, low-density lipoprotein, triglycerides, hemoglobinA1c, glucose, insulin, C-reactive protein, and fibrinogen. Using clinical laboratory cutoffs defined as abnormal, a multisystem risk score was computed representing a sum of the deviation around the cutoffs across the 8 biomarkers. In addition, high risk grouping was classified if subjects exhibited 4 or more biomarkers in the abnormal laboratory range. Results An interaction of time-by-treatment-by-high risk group was found (F(4,197.2)=3.14, p=.02) in which both TCC (p=.04) and CBT (p=.001) showed significantly lower risk scores as compared to SS at 16-months. CBT reduced risk of being in the high risk group at 4-months (odds ratio [OR]=.21 [95%CI, .03–1.47], p<.10) and at 16-months (OR=0.06 [95%CI, .005–.669]; p<.01). TCC reduced the risk at 16-months (OR=.10 [95%CI, .008–1.29]; p<.05) but not at 4 months. Of participants who were classified in the high risk category at baseline, improvements in sleep quality, as defined by a clinical severity threshold, reduced the likelihood of being in the high risk group at 16-months, OR=.08 (95% CI, .008–.78); p = .01. Conclusions and Relevance Participants classified as having high multisystem biological risk at entry and assigned to CBT or TCC show improvements in risk scores after one year follow-up. Given that these clinical biomarkers are associated with cardiovascular, metabolic, and inflammatory disease risk, improving sleep quality has the potential to reduce the risk of chronic disease in older adults with insomnia. Clinical Trial Registration # and name ClinicalTrials.gov: NCT00280020, Behavioral Treatment of Insomnia in Aging

Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms: Findings From the Women’s Health Initiative Study

“…Consistent with findings that symptoms of insomnia increase inflammation(1) and morbidity and mortality risk(7–9; 11; 43), we predicted that greater insomnia symptoms would be associated with an older epigenetic age. Similar to findings of sleep duration with mortality(44), we also predicted that both short and long sleep duration would be associated with greater epigenetic aging.…”

Sleep Disturbance, Daytime Symptoms, and Functional Performance in Patients With Stable Heart Failure

“…For example, cognitive behavioral therapy for insomnia produced large effects on fatigue among HF patients (Redeker et al, 2015), and improved biomarkers of cardiac risk (Carroll et al, 2015; Irwin et al, 2015; Irwin et al, 2014) among a sample of older adults of whom the majority had cardiovascular disorders. Meditation and guided imagery may also be efficacious in improving sleep and sleep-related symptoms among these patients (Kwekkeboom & Bratzke, 2015).…”

Abnormalities in chemokine levels in schizophrenia and their clinical correlates

“…The Multisystem Disease Risk Score (Carroll et al, 2015) was calculated by summing the z-scores of high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, hemoglobin A1c, glucose, insulin, and C-reactive protein levels in blood. The Framingham 10-year Coronary Heart Disease Relative Risk Score (Wilson et al, 1998) was also computed (Jin et al, 2011).…”